33,143 Shares in Inspire Medical Systems, Inc. $INSP Purchased by Osterweis Capital Management Inc.

Key Points

• Osterweis Capital Management Inc. has acquired a new stake in Inspire Medical Systems valued at approximately $5.28 million, representing about 0.11% of the company's shares as of their latest SEC filing.
• Recent reports from analysts indicate varying expectations for Inspire Medical Systems, with Piper Sandler reducing its price target from $233 to $150 while Robert W. Baird increased its target from $230 to $236, signifying mixed sentiments in the market.
• Inspire Medical Systems has announced a $200 million share buyback plan, suggesting confidence in the company's valuation and future performance.

Osterweis Capital Management Inc. acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,143 shares of the company's stock, valued at approximately $5,279,000. Osterweis Capital Management Inc. owned 0.11% of Inspire Medical Systems at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northern Trust Corp lifted its position in Inspire Medical Systems by 6.6% in the first quarter. Northern Trust Corp now owns 260,407 shares of the company's stock worth $41,478,000 after purchasing an additional 16,158 shares during the period. Algert Global LLC lifted its position in Inspire Medical Systems by 39.1% in the first quarter. Algert Global LLC now owns 59,820 shares of the company's stock worth $9,528,000 after purchasing an additional 16,808 shares during the period. American Century Companies Inc. lifted its position in Inspire Medical Systems by 64.4% in the first quarter. American Century Companies Inc. now owns 18,432 shares of the company's stock worth $2,936,000 after purchasing an additional 7,218 shares during the period. Oak Ridge Investments LLC lifted its position in Inspire Medical Systems by 4.8% in the first quarter. Oak Ridge Investments LLC now owns 26,090 shares of the company's stock worth $4,156,000 after purchasing an additional 1,186 shares during the period. Finally, Fox Hill Wealth Management bought a new position in Inspire Medical Systems in the first quarter worth $752,000. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Stock Up 4.6%

Inspire Medical Systems stock traded up $4.1780 during mid-day trading on Friday, hitting $95.7980. 559,798 shares of the company were exchanged, compared to its average volume of 1,655,434. Inspire Medical Systems, Inc. has a 1-year low of $73.92 and a 1-year high of $225.00. The company has a market capitalization of $2.83 billion, a PE ratio of 55.37, a price-to-earnings-growth ratio of 2.99 and a beta of 1.22. The business has a fifty day moving average of $117.55 and a 200 day moving average of $144.47.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.23. The company had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The firm's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company posted $0.32 earnings per share. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its Board of Directors has approved a share buyback program on Monday, August 11th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to repurchase up to 8.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

INSP has been the subject of several research reports. Royal Bank Of Canada reduced their target price on Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating for the company in a research report on Tuesday, August 5th. JPMorgan Chase & Co. cut Inspire Medical Systems from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $195.00 to $110.00 in a research report on Tuesday, August 5th. Robert W. Baird raised their target price on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Wall Street Zen lowered Inspire Medical Systems from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, Leerink Partners dropped their price objective on Inspire Medical Systems from $116.00 to $97.00 and set a "market perform" rating for the company in a research note on Friday, August 15th. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $165.62.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.